Property:Specifications on cancer therapies
This is a property of type Text.
D
Tumors were mainly located at tonsils (20.5%), floor of the mouth (15.7%), or tongue (margin:15.7%, base:12.0%, body:8.4%)
Patients received surgery prior to radiotherapy in n (%):
both arms together: 59 (85.5%)
enzyme-arm: 33 (91.7%)
placebo-arm: 26 (78.8%)
Radiotherapy protocols comprised conventional fractionation with 1.8–2.0 Gy/fraction, 5× per week to total doses of 60–66 Gy per 6–7 weeks, or hyperfractionation with 2 × 1.2 Gy per day, 5× per week to a total dose of 72 Gy per 6–7 weeks. +
E
Ehrenpreis et al. (2005): A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Retinol Palmitate (Vitamin A) for Symptomatic Chronic Radiation Proctopathy +
Time since radiation therapy ''mean (range)'': 4.35 years (0.67-19) +
Emami et al. (2014): Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of green tea in preventing acute gastrointestinal complications due to radiotherapy +
Patients receiving standardized abdomen and pelvic irradiation 5000 cGy (1000 cGy weekly)
Cancer treatments: per arm n(%)
Radiotherapy + chemotherapy: green tea arm 8(38.1); Placebo arm 7(33.3)
Radiotherapy + surgery: green tea arm 16(76.2); Placebo arm 16(76.2) +
Ertekin et al. (2004): Zinc sulfate in the prevention of radiation-induced oropharyngeal mucositis: a prospective, placebo-controlled, randomized study +
22 patients had undergone surgery before radiotherapy, and 8 patients were treated with radiotherapy only (telecobalt radiotherapy (Picker C-9) at 80 cm SSD using conventional fractionation of 2 Gy/fraction, five fractions weekly for 20 –35 fractions within 4 –7 weeks). According to tumor stage, localization, and histologic type, the treatment portals consisted of two lateral parallel opposing fields for the primary tumor and upper cervical lymph nodes and/or an anterior portal field for the lower cervical lymph nodes and supraclavicular lymph nodes. Immobilization with a thermoplastic mask was established for all patients, and individual lead protective blocks were used.
The median radiation dose was 6400 cGy (range 4000– 7000). In the zinc sulfate arm, the median radiation dose was 6600 cGy (range 4000–7000), and in the placebo group, it was 6200 cGy (range 4000 – 6800).
3 patients in the zinc sulfate arm and 3 in the placebo arm were administered concomitant chemoradiotherapy. +
F
Fahimi et al. (2011): Evaluating the Effect of Zingiber Officinalis on Nausea and Vomiting in Patients Receiving Cisplatin Based Regimens +
Cisplatin chemotherapy regimens, n (%)
* Cisplatin + Etoposide 7 (19%)
* Cisplatin + Gemcitabine 7 (19%)
* Cisplatin + Docetaxel 11 (31%)
* Cisplatin + Vinorelbine 4 (11%)
* Cisplatin + Cyclophosphamide + Doxorubicin 4 (11%)
* Cisplatin + Paclitaxel + Doxorubicin 1 (3%)
* Cisplatin + 5-FU + Docetaxel 1 (3%)
* Cisplatin + Pemetrexed 1 (3%) +
Fallahi et al. (2013): Does vitamin E protect salivary glands from I-131 radiation damage in patients with thyroid cancer? +
Postsurgical ablation therapy with 3700–5550MBq <sup>131</sup>I +
Fallon et al. (2017) I: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies +
NI +
Fallon et al. (2017) II: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies +
NI +
Ferreira et al. (2004): Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: A double-blind randomized trial +
"Radiotherapy was provided by a Cobalt 60 unit (Theratron Phoenix) operating at 80-cm target-skin distance. Two parallel opposed fields were designed with customized alloy shielding blocks to include the tumor within a 2-cm safe margin and the upper cervical lymph nodes bilaterally. Anterior supraclavicular fields were added whether metastatic cervical lymph nodes were present or the primary tumor was located in the tonsils or tongue. A daily dose of 2 Gy/section 5 days a week was calculated at the midline up to a cumulative dose of 44 Gy/4.5 weeks. A first field reduction was made for the spinal cord, sparing up to the dose of 60 Gy/6 weeks. A second reduction was made to encompass only the tumor within 1-cm margins up to the final dose of 70 Gy/7 weeks. Patients previously treated with complete or incomplete resections were planned to receive total doses of 50 or 60 Gy in 5 and 6 weeks, respectively, with a similar technique." +
Frankling et al. (2021): ‘Palliative-D’ - Vitamin D Supplementation to Palliative Cancer Patients: A Double Blind, Randomized Placebo-Controlled Multicenter Trial +
With no intention to cure +
Freedland et al. (2020): A Randomized Controlled Trial of a 6-month low carbohydrate intervention on disease progression in men with recurrent prostate cancer: Carbohydrate and Prostate Study 2 (CAPS2) +
n = 45
Surgery, n (%): 36 (80)
Radiation, n (%): 9 (20) +
G
Ghoreishi et al. (2007): Effect of vitamin E on chemotherapy-induced mucositis and neutropenia in leukemic patients undergoing bone marrow transplantation +
Allogenic bone marrow transplantation
"All the patients received cyclophosphamide 60 mg/kg for 2 days (on day -2 and -3, total dose 120 mg/kg) and busulfan 4 mg/kg for 4 days (on day -7 until day -4, total dose 16 mg/kg) as the conditioning regimen. In order to prevent GVHD, cyclosporine A 3 mg/kg/day i.v. was administered 3 days before BMT until the 5th day after BMT. Thereafter, oral cyclosporine A at 12.5 mg/kg/day was begun. Moreover, methotrexate 10 mg/m²/day i.v. for one day (+1) and 6 mg/m²/day for 3 days (+3, +6, and +11) was administered. Established GVHD was treated with a combination of intravenous methyl prednisolone and then oral prednisolone. All the patients received granulocyte colony stimulating factor 300 mg/day i.v. until their absolute neutrophil count returned to 1000 cells/mL for 3 consecutive days." +
Goossens et al. (2016): Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial +
NA +
Gorgu et al. (2013): The effect of zinc sulphate in the prevention of radiation induced oral mucositis in patents with head and neck cancer +
Median radiation dose in all the patients was 6440 cGy (range: 4600‐7000 cGy);
intervention arm: 6625 cGy (range: 6000‐7000 cGy) vs. control arm: 6316 cGy (range: 4600‐7000 cGy);
n=20 with concurrent chemotherapy;
n=24 with surgery before radiotherapy +
Grimison et al. (2020): Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial +
Moderate-to-high emetogenic intravenous chemotherapy
Chemotherapy regimen, n(%):
Doxorubicin + cyclophosphamide = 20 (26)
FOLFOX ± biological = 13 (17)
Cisplatin based = 12 (15)
FOLFIRINOX = 6 (8)
Other = 27 (35) +
Gujral et al. (2001): Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers +
All patients received 50 to 70 Gy telecobalt therapy using a standard daily radiation dose of 2 Gy in 25-35 fractions over a period of 6-7 weeks +
H
Hajimohammadebrahim-Ketabforoush et al. (2019): Effect of Vitamin D Supplementation on Postcraniotomy Pain After Brain Tumor Surgery: A Randomized Clinical Trial +
The patients undergoing general anesthesia were induced with thiopental sodium 5e7 mg/kg, fentanyl 5 mg/kg, midazolam 0.02 mg/kg, lidocaine 1 mg/kg, atracurium 0.5 mg/kg, endotracheal intubation, and maintained with propofol 50e150 mg/kg/min in a 3 L/min oxygen/air mixture. Eventually, the patient’s awakening was induced with neostigmine and atropine to an extent of 0.07 mg/kg and 0.02 mg/kg, respectively. +
Halyard et al. (2007): Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4) +
Planned radiation dose ≥6,000 vs. ≤6,000 cGy;
n=71 with concomitant chemotherapy anticipated +
Heggie et al. (2002): A phase III study on the efficacy of topical aloe vera gel on irradiated breast tissue +
Chemotherapy per arm (n):
Aloe vera arm: yes = 24; no = 83
Placebo arm: yes = 24; no = 77 +
Hejazi et al. (2013): A pilot clinical trial of radioprotective effects of curcumin supplementation in patients with prostate cancer +
External beam radiotherapy (EBRT), in combination with hormone ablation +